SEC 13F Intelligence

Glenview Trust Co / LLY

Glenview Trust Co’s Eli Lilly & Co Position

Does Glenview Trust Co own Eli Lilly & Co (LLY)? Yes — 188.4K shares worth $173M (+2.72% of its 13F portfolio) as of Q1 2026, down from 189.8K shares the prior filed quarter.

Position Value
$173M
Q1 2026
Shares
188.4K
% of Portfolio
+2.72%
Quarters Held
30
currently held

Position History LLY

Reported value by quarter
Q4 ’18: $9MQ4 ’18Q1 ’19: $10MQ2 ’19: $9MQ3 ’19: $9MQ4 ’19: $10MQ4 ’19Q1 ’20: $11MQ2 ’20: $12MQ3 ’20: $11MQ4 ’20: $12MQ4 ’20Q1 ’21: $22MQ2 ’21: $32MQ3 ’21: $33MQ4 ’21: $41MQ4 ’21Q1 ’22: $43MQ2 ’22: $46MQ3 ’22: $45MQ4 ’22: $51MQ4 ’22Q1 ’23: $80MQ2 ’23: $99MQ3 ’23: $106MQ4 ’23: $115MQ4 ’23Q1 ’24: $154MQ2 ’24: $175MQ3 ’24: $168MQ4 ’24: $147MQ4 ’24Q1 ’25: $156MQ2 ’25: $148MQ3 ’25: $146MQ4 ’25: $204MQ4 ’25Q1 ’26: $173Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026188.4K$173M+2.72%
Q4 2025189.8K$204M+3.15%
Q3 2025190.8K$146M+2.31%
Q2 2025190.3K$148M+2.57%
Q1 2025189.1K$156M+3.03%
Q4 2024190.5K$147M+2.76%
Q3 2024190.0K$168M+3.24%
Q2 2024193.1K$175M+3.52%
Q1 2024197.6K$154M+3.30%
Q4 2023196.5K$115M+2.81%
Q3 2023197.5K$106M+2.93%
Q2 2023211.2K$99M+2.70%
Q1 2023233.0K$80M+2.40%
Q4 2022138.2K$51M+1.68%
Q3 2022140.6K$45M+1.72%
Q2 2022142.7K$46M+1.70%
Q1 2022151.1K$43M+1.41%
Q4 2021146.8K$41M+1.34%
Q3 2021143.2K$33M+1.28%
Q2 2021140.1K$32M+1.24%
Q1 2021120.1K$22M+0.97%
Q4 202072.4K$12M+0.57%
Q3 202072.8K$11M+0.56%
Q2 202074.4K$12M+0.70%
Q1 202077.5K$11M+0.75%
Q4 201977.5K$10M+0.57%
Q3 201979.0K$9M+0.53%
Q2 201976.9K$9M+0.53%
Q1 201979.3K$10M+0.66%
Q4 201879.6K$9M+0.68%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Glenview Trust Co’s full portfolio or all institutional holders of LLY.